The Role of the Reactive Oxygen Species Scavenger Agent, Astaxanthin, in the Protection of Cisplatin-Treated Patients Against Hearing Loss

Drug Des Devel Ther. 2019 Dec 18:13:4291-4303. doi: 10.2147/DDDT.S212313. eCollection 2019.

Abstract

Emerging evidence of significant hearing loss occurring shortly after cisplatin administration in cancer patients has stimulated research into the causes and treatment of this side effect. Although the aetiology of cisplatin-induced hearing loss (CIHL) remains unknown, an increasing body of research suggests that it is associated with excessive generation of intracellular reactive oxygen species (ROS) in the cochlea. Astaxanthin, a xanthophyll carotenoid, has powerful anti-oxidant, anti-inflammatory, and anti-apoptotic properties based on its unique cell membrane function, diverse biological activities, and ability to permeate the blood-brain barrier. In this review, we summarize the role of ROS in CIHL and the effect of astaxanthin on inhibiting ROS production. We focus on investigating the mechanism of action of astaxanthin in suppressing excessive production of ROS.

Keywords: astaxanthin; cisplatin; hearing loss; oxidative stress.

Publication types

  • Review

MeSH terms

  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Cisplatin / adverse effects*
  • Cisplatin / antagonists & inhibitors*
  • Cisplatin / therapeutic use
  • Free Radical Scavengers / metabolism
  • Free Radical Scavengers / pharmacology*
  • Hearing Loss / drug therapy
  • Hearing Loss / prevention & control*
  • Humans
  • Reactive Oxygen Species / metabolism*
  • Xanthophylls / metabolism
  • Xanthophylls / pharmacology

Substances

  • Free Radical Scavengers
  • Reactive Oxygen Species
  • Xanthophylls
  • astaxanthine
  • Cisplatin